Loading clinical trials...
Loading clinical trials...
A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Novartis Investigative Site
Orange, California, United States
National Institutes of Health
Bethesda, Maryland, United States
Novartis Investigative Site
Columbus, Ohio, United States
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Padua, PD, Italy
Start Date
February 4, 2014
Primary Completion Date
April 13, 2016
Completion Date
April 13, 2016
Last Updated
January 5, 2021
37
ACTUAL participants
BVS857
DRUG
Placebo
DRUG
Lead Sponsor
Novartis Pharmaceuticals
NCT04944940
NCT03555578
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06169046